Aerpio Pharmaceuticals, Inc.
ARPONASDAQHealthcare
$2.20
$-0.02(-0.90%)
Market Cap$53669220
P/E Ratio—
52W High$2.3
52W Low$2.16
Aerpio Pharmaceuticals, Inc. (ARPO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARPO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.14M | $25.98M | $5.51M | $4.47M | $0.82M |
| Cost of Revenue | $0.00M | $0.00M | $35.02M | $20.02M | $14.44M |
| Gross Profit | $0.00M | $0.00M | ($29.51M) | ($15.54M) | ($13.62M) |
| Gross Margin %(computed) | 0.00% | 0.00% | -535.75% | -347.36% | — |
| Operating Expenses | |||||
| R&D Expenses | $90.96M | $51.03M | $35.02M | $20.02M | $14.44M |
| G&A Expenses | $0.00M | $0.00M | $7.44M | $8.28M | $7.97M |
| Total Operating Expenses | $121.55M | $93.44M | $7.44M | $7.55M | $7.96M |
| Operating Income | ($114.40M) | ($67.46M) | ($36.95M) | ($23.82M) | ($21.59M) |
| Operating Margin %(computed) | — | -259.62% | -670.77% | -532.45% | — |
| Interest Income | $6.23M | $3.92M | $0.03M | $0.06M | $0.60M |
| Interest Expense | $0.00M | ($0.15M) | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($20.60M) | ($63.69M) | ($36.92M) | ($23.16M) | ($22.18M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($20.60M) | ($63.69M) | ($36.92M) | ($23.16M) | ($22.18M) |
| Net Margin %(computed) | -288.26% | -245.13% | -670.24% | -517.55% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.33 | $-2.36 | $-1.08 | $-0.96 | $-1.35 |
| Wtd Avg Shares | 618.87M | 27.03M | 34.29M | 24.10M | 16.42M |
| EBITDA | ($114.40M) | ($67.46M) | ($36.05M) | ($22.65M) | ($20.47M) |
| EBITDA Margin %(computed) | — | -259.62% | -654.58% | -506.33% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Aerpio Pharmaceuticals, Inc. data
About Aerpio Pharmaceuticals, Inc. (ARPO) Income Statement
Aerpio Pharmaceuticals, Inc. (ARPO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ARPO reported revenue of $0.01B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.02B) — a net profit margin of -288.26%.
Frequently asked questions
ARPO · 4 questionsAerpio Pharmaceuticals, Inc. (ARPO) reported revenue of $0.01B for 2025, down 72.5% year-over-year.
ARPO revenueARPO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09